nach oben

World Journal of Surgery

Erschienen in:

01.07.2015 | Original Scientific Report

VEGF-D and A Preoperative Serum Levels Predict Nodal and Distant Metastases in Differentiated Thyroid Cancer Patients

verfasst von: Chieh-Wen Lai, Quan-Yang Duh, Chuang-Wei Chen, Fu-Jie Chuang, Yao-Jen Chang, Ming-Tsan Lin, Ming-Hsun Wu

Erschienen in: World Journal of Surgery | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Preoperative tumor aggressiveness biomarkers may help surgeons decide the extent of an operation. However, whether serum angiogenetic factors can be used to predict the prognosis of patients with differentiated thyroid cancer is still unclear.

Methods

Seventy-six DTC patients were prospectively recruited. Preoperative serum samples were collected and measured for Tie-2, Ang-1, Ang-2, VEGF-A, and VEGF-D levels. The potential correlations between their serum levels and clinicopathologic features as well as their prognoses were analyzed.

Results

Older age (>45 years old) and higher VEGF-A serum levels were independent predictors of extrathyroidal extension. The VEGF-D serum level was an independent factor for lymph node metastases and VEGF-A was an independent factor for distant metastases. None of these serum angiogenetic factors were significantly different between patients who were disease free and those with recurrences. The presence of lymph node metastases was the only independent factor for recurrence over the 2-year follow-up.

Conclusion

Preoperative serum VEGF-A and VEGF-D levels were significantly elevated in DTC patients with distant and lymph node metastases. These findings, when combined with other clinicopathological factors, may help in surgical decisions.

Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338:297–306PubMedCrossRef

Alitalo K, Mohla S, Ruoslahti E (2004) Lymphangiogenesis and cancer: meeting report. Cancer Res 64:9225–9229PubMedCrossRef

Alitalo K, Carmeliet P (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1:219–227PubMedCrossRef

Park JH, Park KJ, Kim YS et al (2007) Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132:200–206PubMedCrossRef

Yalcin M, Dyskin E, Lansing L et al (2010) Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 95:1972–1980PubMedCrossRef

Wray CJ, Rilo HL, Ahmad SA (2004) Colon cancer angiogenesis and antiangiogenic therapy. Expert Opin Investig Drugs 13:631–641PubMedCrossRef

Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10:165–177PubMedCrossRef

Ferrara N (2009) Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 29:789–791PubMedCrossRef

Lohela M, Bry M, Tammela T, Alitalo K (2009) VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21:154–165PubMedCrossRef

10.

Huang H, Bhat A, Woodnutt G, Lappe R (2010) Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10:575–585PubMedCrossRef

11.

Saharinen P, Eklund L, Pulkki K et al (2011) VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 17:347–362PubMedCrossRef

12.

Peters KG, Kontos CD, Lin PC et al (2004) Functional significance of Tie2 signaling in the adult vasculature. Recent Prog Horm Res 59:51–71PubMedCrossRef

13.

Abdallah A, Belal M, El Bastawisy A, Gaafar R (2014) Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer. Oncol Lett 7:2121–2129PubMedCentralPubMed

14.

Yang B, Gu W, Peng B et al (2012) High level of circulating endothelial progenitor cells positively correlates with serum vascular endothelial growth factor in patients with renal cell carcinoma. J Urol 188:2055–2061PubMedCrossRef

15.

Jelkmann W (2001) Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47:617–623PubMed

16.

Sobin LH, Fleming ID (1997) TNM Classification of Malignant Tumors, 5th edition . Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80:1803–1804

17.

Ramsden JD (2000) Angiogenesis in the thyroid gland. J Endocrinol 166:475–480PubMedCrossRef

18.

Salcedo X, Medina J, Sanz-Cameno P et al (2005) The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology 42:696–701PubMedCrossRef

19.

Bunone G, Vigneri P, Mariani L et al (1999) Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 155:1967–1976PubMedCentralPubMedCrossRef

20.

Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401–410PubMedCrossRef

21.

Viglietto G, Maglione D, Rambaldi M et al (1995) Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569–1579PubMed

22.

Yu XM, Lo CY, Lam AK et al (2008) Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann Surg 247:483–489PubMedCrossRef

23.

de Araujo-Filho VJ, Alves VA, de Castro IV et al (2009) Vascular endothelial growth factor expression in invasive papillary thyroid carcinoma. Thyroid 19:1233–1237PubMedCrossRef

24.

Soh EY, Duh QY, Sobhi SA et al (1997) Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82:3741–3747PubMed

25.

Klein M, Vignaud JM, Hennequin V et al (2001) Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 86:656–658PubMedCrossRef

26.

Zhou ZH, Cui XN, Xing HG et al (2013) Changes and prognostic value of serum vascular endothelial growth factor in patients with differentiated thyroid cancer. Med Princ Pract 22:24–28PubMedCrossRef

27.

Karaca Z, Tanriverdi F, Unluhizarci K et al (2011) VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 164:277–284PubMedCrossRef

28.

Bassiouny AR, Zaky A, Neenaa HM (2010) Synergistic effect of celecoxib on 5-fluorouracil-induced apoptosis in hepatocellular carcinoma patients. Ann Hepatol 9:410–418PubMed

29.

Kwon KA, Kim SH, Oh SY et al (2010) Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 10:203PubMedCentralPubMedCrossRef

30.

Villarejo-Campos P, Padilla-Valverde D, Martin RM et al (2013) Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer. Clin Transl Oncol 15:265–270PubMedCrossRef

31.

Ringel MD, Anderson J, Souza SL et al (2001) Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol 14:289–296PubMedCrossRef

32.

Noguchi S, Murakami N, Yamashita H et al (1998) Papillary thyroid carcinoma: modified radical neck dissection improves prognosis. Arch Surg 133:276–280PubMedCrossRef

33.

Mazzaferri EL, Young RL (1981) Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511–518PubMedCrossRef

34.

Hughes CJ, Shaha AR, Shah JP, Loree TR (1996) Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck 18:127–132PubMedCrossRef

35.

Jukkola A, Bloigu R, Ebeling T et al (2004) Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer 11:571–579PubMedCrossRef

36.

Forest VI, Clark JR, Ebrahimi A et al (2011) Central compartment dissection in thyroid papillary carcinoma. Ann Surg 253:123–130PubMedCrossRef

37.

Shen WT, Ogawa L, Ruan D et al (2010) Central neck lymph node dissection for papillary thyroid cancer: the reliability of surgeon judgment in predicting which patients will benefit. Surgery 148:398–403PubMedCrossRef

38.

Alitalo K, Tammela T, Petrova TV (2005) Lymphangiogenesis in development and human disease. Nature 438:946–953PubMedCrossRef

39.

Nakamura Y, Yasuoka H, Tsujimoto M et al (2003) Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer. Clin Cancer Res 9:5313–5317PubMed

40.

Yasuoka H, Nakamura Y, Zuo H et al (2005) VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 18:1127–1133PubMedCrossRef

41.

Tanaka K, Kurebayashi J, Sonoo H et al (2002) Expression of vascular endothelial growth factor family messenger RNA in diseased thyroid tissues. Surg Today 32:761–768PubMedCrossRef

42.

Lai CW, Chen KY, Hung CS et al (2011) Serum vascular endothelial growth factor-D levels correlate with cervical lymph node metastases in papillary thyroid carcinoma. Growth Factors 29:57–62PubMedCrossRef

43.

Nersita R, Matrone A, Klain M et al (2012) Decreased serum vascular endothelial growth factor-D levels in metastatic patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 76:142–146CrossRef

44.

Niedzwiecki S, Stepien T, Kopec K et al (2006) Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers. Cytokine 36:291–295PubMedCrossRef

45.

Mitsutake N, Namba H, Takahara K et al (2002) Tie-2 and angiopoietin-1 expression in human thyroid tumors. Thyroid 12:95–99PubMedCrossRef

46.

Hsueh C, Lin JD, Wu IC et al (2011) Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma. J Surg Oncol 103:395–399PubMedCrossRef

47.

Xing M, Westra WH, Tufano RP et al (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373–6379PubMedCrossRef

48.

Kebebew E, Weng J, Bauer J et al (2007) The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246:466–470 discussion 470–461PubMedCentralPubMedCrossRef

49.

Durante C, Tallini G, Puxeddu E et al (2011) BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. Eur J Endocrinol 165:455–463PubMedCrossRef

50.

Hughes DT, Miller BS, Cohen MS et al (2014) Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin. Ann Surg Oncol 21:1647–1652PubMedCrossRef

51.

Ito Y, Kudo T, Kobayashi K et al (2012) Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J Surg 36:1274–1278. doi:10.1007/s00268-012-1423-5 PubMedCrossRef

52.

Mondul AM, Rager HC, Kopp W et al (2011) Supplementation with alpha-tocopherol or beta-carotene reduces serum concentrations of vascular endothelial growth factor-D, but Not -A or -C, in male smokers. J Nutr 141:2030–2034PubMedCentralPubMedCrossRef

Titel: VEGF-D and A Preoperative Serum Levels Predict Nodal and Distant Metastases in Differentiated Thyroid Cancer Patients
verfasst von: Chieh-Wen Lai
Quan-Yang Duh
Chuang-Wei Chen
Fu-Jie Chuang
Yao-Jen Chang
Ming-Tsan Lin
Ming-Hsun Wu
Publikationsdatum: 01.07.2015
Verlag: Springer International Publishing
Erschienen in: World Journal of Surgery / Ausgabe 7/2015
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-015-3016-6

Neu im Fachgebiet Chirurgie

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

Real-World-Daten sprechen eher für Dupilumab als für Op.

14.05.2024 Rhinosinusitis Nachrichten

Zur Behandlung schwerer Formen der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) stehen seit Kurzem verschiedene Behandlungsmethoden zur Verfügung, darunter Biologika, wie Dupilumab, und die endoskopische Sinuschirurgie (ESS). Beim Vergleich der beiden Therapieoptionen war Dupilumab leicht im Vorteil.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

VEGF-D and A Preoperative Serum Levels Predict Nodal and Distant Metastases in Differentiated Thyroid Cancer Patients